News|Articles|September 22, 2023
CGTLive’s Weekly Rewind – September 22, 2023
Author(s)CGTLive Staff
Review top news and interview highlights from the week ending September 22, 2023.
Advertisement
Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.
1. Taysha Gene Therapies Drops Development of Giant Axonal Neuropathy Gene Therapy TSHA-120
The company is now prioritizing its gene therapy program for Rett syndrome.
2. Pat Furlong, BSN, RN, on the State of Gene Therapy in Muscular Dystrophy
The founding president and chief executive officer of Parent Project Muscular Dystrophy discussed recent and upcoming milestones in the field.
3. Research Identifies Cell Signatures of CAR T-Cells in Long Remission
Cells from patients with ALL treated in the CARPALL study were analyzed and sequenced.
4. Deborah Phippard, PhD, on the History and Current State of Gene Therapy for Neurological Indications
The chief scientific officer of Precision for Medicine discussed the previous and current delivery methods used for gene therapies and new innovations on the horizon.
5. Orchard Therapeutics’ BLA for Metachromatic Leukodystrophy Cell Therapy Arsa-Cel Accepted With Priority Review
The PDUFA data has been set for March 18, 2024.
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Advertisement
Related Articles
CGTLive®’s Weekly Rewind – September 12, 2025September 12th 2025
Around the Helix: Cell and Gene Therapy Company Updates – September 10, 2025September 10th 2025
Advertisement
Advertisement
